Edition:
United States

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

260.04USD
19 Sep 2018
Change (% chg)

$0.29 (+0.11%)
Prev Close
$259.75
Open
$260.31
Day's High
$260.99
Day's Low
$259.17
Volume
205,598
Avg. Vol
271,263
52-wk High
$263.25
52-wk Low
$191.53

Select another date:

Fri, May 11 2018

Photo

U.S. investigates bloodstream infections for link to heparin syringes

SHANGHAI/CHICAGO Health agencies are investigating an outbreak of bloodstream infections in children from four U.S. states that may be linked to heparin and saline syringes made by Becton Dickinson and Co, the agencies told Reuters. The U.S. Centers for Disease Control and Prevention has confirmed 14 cases of bloodstream infections in children caused by the same strain of the Serratia marcescens bacterium, the agency's lead investigator on the outbreak said in a telephone interview.

U.S. investigates bloodstream infections for link to heparin syringes

* 14 children in 4 states have confirmed bloodstream infections

BRIEF-Becton Dickinson Reports Q2 Loss Per Share $0.19

* BD ANNOUNCES RESULTS FOR 2018 SECOND FISCAL QUARTER; RAISES FISCAL 2018 GUIDANCE

BRIEF-Becton Dickinson Files For Potential Mixed Shelf Offering

* BECTON DICKINSON AND CO FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2HvryvV) Further company coverage:

BRIEF-Becton Dickinson Updates Instructions for Use for Certain BD Vacutainer Blood Collection Tubes

* BECAME AWARE OF CONCERNS ABOUT INACCURATE LEAD TEST RESULTS FROM MAGELLAN DIAGNOSTICS LEADCARE TESTING SYSTEMS

Select another date: